Press Releases June 1, 2026 08:00 AM

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Amneal Pharmaceuticals to Present at Goldman Sachs 47th Annual Global Healthcare Conference 2026

By Ajmal Hussain AMRX

Amneal Pharmaceuticals, a diversified biopharmaceutical company specializing in affordable and innovative medicines, announced that Co-CEO Chirag Patel will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation will be webcast live and provide insights into the company's diverse portfolio and growth strategy.

Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
AMRX

Key Points

  • Amneal will present at a high-profile global healthcare conference, increasing visibility among investors.
  • The company has a diverse portfolio of about 300 generic, specialty, and biosimilar medicines with substantial annual prescription volume mainly in the U.S.
  • Amneal's business segments include Affordable Medicines (generics, injectables, biosimilars), Specialty (neurology and endocrinology branded treatments), and AvKARE distribution segment, targeting federal and retail customers.

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47th Annual Global Healthcare Conference 2026 being held on June 8-10 at the Loews Miami Beach Hotel in Miami, FL.

A company presentation will take place on Tuesday June 9, 2026, at 8:40AM EDT. A live webcast of the presentation will be available here.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
[email protected]


Risks

  • Market competition and regulatory challenges in generic and specialty pharmaceutical sectors could impact product approvals and market share.
  • Execution risk related to the company’s growth strategy and product portfolio expansion may affect financial performance.
  • Dependence on U.S. healthcare policies and reimbursement environments could present uncertainties affecting revenues.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026